Publication Cover
Synthetic Communications
An International Journal for Rapid Communication of Synthetic Organic Chemistry
Volume 49, 2019 - Issue 17
923
Views
8
CrossRef citations to date
0
Altmetric
Articles

2-Phenylindole derivatives as anticancer agents: synthesis and screening against murine melanoma, human lung and breast cancer cell lines

, , , , , ORCID Icon, & ORCID Icon show all
Pages 2258-2269 | Received 06 Feb 2019, Published online: 19 Jun 2019
 

Abstract

Indole derivatives have attractive anticancer properties and may be a future hope for better anticancer drug(s) of low toxicity and high potency. In this paper, syntheses of 2-phenylindole derivatives have been described via Fischer indole synthesis through a one-pot solvent-free method. The synthesized compounds were screened for anticancer potential in vitro against murine melanoma (B16F10), human lung cancer (A549), and human breast cancer (MDA-MB-231) cell lines. The results highlighted that 2-phenylindole derivatives are also promising anticancer agents in case of melanoma and lung cancer along with the breast cancer. Molecular docking analyses with possible targets for melanoma (NEDD4-1) and lung cancer (EGFR) were also performed to understand specific interactions of 2-phenylindole derivatives with the amino acid residues of the receptors.

GRAPHICAL ABSTRACT

Acknowledgments

The authors thank Sophisticated Instrumentation Center, Dr. Harisingh Gour University, Sagar, for recording NMR spectral data and HRMS of our compounds.

Additional information

Funding

SG and KD are thankful to the University Grants Commission (UGC), New Delhi for Startup grants No. F.30-106/2015-BSR and No. F.30-56/2014 BSR, respectively.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.